Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia A (Factor VIII) (Aug 2019)

Posted by Matt Breese on Aug 23, 2019

Find me on:

According to our recent payer coverage analysis for hemophilia A (factor VIII) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia A (factor VIII) treatments shows that under the pharmacy benefit, about 34% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Hemophilia A Factor VIII_2Q2019Data snapshot as of Q2 2019

Trends: PBMs are increasingly focused on offering high-touch condition management services that give them a more active role in patient care. For example, AscellaHealth, LLC harnesses a variety of resources to help better manage treatment for hemophilia.    

To read the full Reality Check on Hemophilia A (Factor VIII) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing